Testing lung adenocarcinomas for ALK rearrangements has become standard practice since remarkable responses in ALK rearrangement-positive NSCLC patients treated with oral TKIs (i.e., alectinib, brigatinib, ceritinib, crizotinib, lorlatinib) have been documented [84]. Here, ALK is linked to lung adenocarcinoma.